 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | sotevtamab (AB-16B5) / Alethia BioTherap
Trial primary completion date, Metastases: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov) - Sep 15, 2023
P2, N=35, Active, not recruiting, Sponsor: Alethia Biotherapeutics
Trial primary completion date: Mar 2023 --> Dec 2023
- | sotevtamab (AB-16B5) / Alethia BioTherap
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov) - Nov 10, 2022
P2, N=35, Active, not recruiting, Sponsor: Alethia Biotherapeutics
Trial primary completion date: Mar 2023 --> Dec 2023 Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- | sotevtamab (AB-16B5) / Alethia BioTherap
Trial completion date, Trial primary completion date, Metastases: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov) - Jul 28, 2022
P2, N=40, Recruiting, Sponsor: Alethia Biotherapeutics
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023 Trial completion date: Jul 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
- || sotevtamab (AB-16B5) / Alethia BioTherap
Enrollment open, Metastases: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov) - Apr 20, 2021
P2, N=40, Recruiting, Sponsor: Alethia Biotherapeutics
Trial completion date: Jul 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- || AB-16B5 / Alethia BioTherap
#AlethiaBiotherapeutics Announces Receipt of #FDA Authorization to Begin Phase 2 Development for its #EMTInhibitor, #AB16B5 https://t.co/LLF9eooQ4o (Twitter) - May 21, 2020
- || sotevtamab (AB-16B5) / Alethia BioTherap
New P2 trial, Metastases: AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) (clinicaltrials.gov) - Apr 27, 2020
P2, N=40, Not yet recruiting, Sponsor: Alethia Biotherapeutics
- | sotevtamab (AB-16B5) / Alethia BioTherap
Trial completion, Enrollment change, Trial primary completion date, Metastases: Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (clinicaltrials.gov) - Jun 28, 2017
P1, N=15, Completed, Sponsor: Alethia Biotherapeutics
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Oct 2016 --> Jan 2017
- sotevtamab (AB-16B5) / Alethia BioTherap
Trial primary completion date, Metastases: Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (clinicaltrials.gov) - Jul 19, 2016
P1, N=20, Recruiting, Sponsor: Alethia Biotherapeutics
Recruiting --> Completed | N=20 --> 15 | Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Jun 2016 --> Oct 2016
- sotevtamab (AB-16B5) / Alethia BioTherap
Enrollment open, Metastases: Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (clinicaltrials.gov) - May 21, 2015
P1, N=20, Recruiting, Sponsor: Alethia Biotherapeutics
Trial primary completion date: Jun 2016 --> Oct 2016 Not yet recruiting --> Recruiting
- sotevtamab (AB-16B5) / Alethia BioTherap
New P1 trial, Metastases: Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy (clinicaltrials.gov) - Apr 9, 2015
P1, N=20, Not yet recruiting, Sponsor: Alethia Biotherapeutics